Skip to content
The Bottom Line on Isentress episode artwork

Oct 23, 2007 17 min

The Bottom Line on Isentress

from TheBody.com: Podcast Central

On Oct. 12, the U.S. Food and Drug Administration approved Isentress, the first member of a new class of meds called integrase inhibitors. Isentress is also known generically as raltegravir, and during its early development was called MK-0518. To find out more about Isentress and how it might impact treatment for HIV-positive people, we spoke with Dr. David Wohl, an associate professor of medicine at the University of North Carolina-Chapel Hill, and the co-director of HIV services for the North Carolina Department of Corrections. Dr. Wohl has participated in research on Isentress, and has also received research funding from Merck and Company, which developed Isentress. This is Part I of an update on Isentress.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

The Bottom Line on Isentress

0:00 17:54

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of TheBody.com: Podcast Central?

This episode is 17 minutes long.

When was this TheBody.com: Podcast Central episode published?

This episode was published on October 23, 2007.

Can I download this TheBody.com: Podcast Central episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.